A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
For patients with human papillomavirus (HPV) type 16 (HPV16)-positive cervical intraepithelial neoplasia grade 3 (CIN3), vaccination with a replication-incompetent Semliki Forest virus vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback